GSA Capital Partners’s Acceleron Pharma XLRN Stock Holding History

GSA Capital Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,543	Closed	-$1.16M	–	1726
2021 Q1	$1.16M	Buy	+8,543	New	+$1.1M	0.19%	108
2020 Q1	–	Sell	-13,357	Closed	-$708K	–	1733
2019 Q4	$708K	Buy	+13,357	New	+$609K	0.08%	417
2019 Q2	–	Sell	-5,085	Closed	-$237K	–	1848
2019 Q1	$237K	Buy	+5,085	New	+$223K	0.02%	1138
2017 Q4	–	Sell	-40,099	Closed	-$1.5M	–	1910
2017 Q3	$1.5M	Buy	+40,099	New	+$1.39M	0.1%	286
2017 Q2	–	Sell	-84,500	Closed	-$2.24M	–	2042
2017 Q1	$2.24M	Buy	+84,500	New	+$2.23M	0.12%	213

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

GSA Capital Partners's XLRN Position: Q2 2021 in Review

GSA Capital Partners sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 8,543 shares — an estimated $1.16M sold.

GSA Capital Partners first reported a position in XLRN in Q1 2017 and held it in 5 quarters. The position peaked at $2.24M in Q1 2017. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

GSA Capital Partners reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
GSA Capital Partners sold 8,543 Acceleron Pharma shares in Q2 2021, an estimated $1.16M.
GSA Capital Partners first reported a position in Acceleron Pharma in Q1 2017 and held it in 5 quarters.
GSA Capital Partners's Acceleron Pharma position peaked at $2.24M in Q1 2017.
271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.